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Background: Physiologically-based population pharmacokinetic modeling (popPBPK) coupled with in 23 
vitro biopharmaceutics tools such as biorelevant dissolution testing can serve as a powerful tool to 24 
establish virtual bioequivalence and set clinically relevant specifications. One of several applications of 25 
popPBPK modeling is in the emerging field of virtual bioequivalence (VBE), where it can be used to 26 
streamline drug development by implementing model-informed formulation design and to inform 27 
regulatory decision-making e.g., with respect to evaluating the possibility of extending BCS-based 28 
biowaivers beyond BCS Class I and III compounds in certain cases.  29 
Methods: In this study, Naproxen, a BCS class II weak acid was chosen as the model compound. In vitro 30 
biorelevant solubility and dissolution experiments were performed and the resulting data were used 31 
as an input to the PBPK model, following a stepwise workflow for the confirmation of the 32 
biopharmaceutical parameters. The naproxen PBPK model was developed by implementing a middle-33 
out approach and verified against clinical data obtained from the literature. Once confidence in the 34 
performance of the model was achieved, several in vivo dissolution scenarios, based on model-based 35 
analysis of the in vitro data, were used to simulate clinical trials in healthy adults. Inter-occasion 36 
variability (IOV) was also added to critical physiological parameters and mechanistically propagated 37 
through the simulations. The various trials were simulated on a “worst/best case” dissolution scenario 38 
and average bioequivalence was assessed according to Cmax, AUC and tmax.  39 
Results: VBE results demonstrated that naproxen products with in vitro dissolution reaching 85% 40 
dissolved within 90 minutes would lie comfortably within the bioequivalence limits for Cmax and AUC. 41 
Based on the establishment of VBE, a dissolution “safe space” was designed and a clinically relevant 42 
specification for naproxen products was proposed. The interplay between formulation-related and 43 
drug-specific PK parameters (e.g., t1/2) to predict the in vivo performance was also investigated. 44 
Conclusion: Over a wide range of values, the in vitro dissolution rate is not critical for the clinical 45 
performance of naproxen products and therefore naproxen could be eligible for BCS-based biowaivers 46 
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based on in vitro dissolution under intestinal conditions. This approach may also be applicable to other 47 
poorly soluble acidic compounds with long half-lives, providing an opportunity to streamline drug 48 
development and regulatory decision-making without putting the patient at a risk. 49 
 50 
Key words: PBPK, modeling & simulation; virtual bioequivalence; IVIVE, clinically relevant 51 
specifications; dissolution safe-space; biorelevant dissolution 52 
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1 Introduction 92 
 93 
Physiologically-based population pharmacokinetic (popPBPK) modelling has been implemented 94 
successfully to support and inform drug product development and regulatory decision-95 
making.(Babiskin and Zhang, 2015; Doki et al., 2017; Heimbach et al., n.d.; Mitra, 2019; Olivares-96 
Morales et al., 2016; Parrott et al., 2014; Pepin et al., 2016; Stillhart et al., 2017; Suarez-Sharp et al., 97 
2018; Zhang et al., 2017) Patient-centric, model-informed drug product development necessitates an 98 
in vitro-in vivo-in silico link to establish clinically relevant specifications and thus guarantee the quality 99 
of the drug product with respect to safety and efficacy. By encompassing model-informed formulation 100 
selection and prediction of clinical performance, modeling and simulation (M & S) provides a way 101 
forward to the design of “safe spaces”, and thus offer regulatory relief. Some examples include guiding 102 
development of biorelevant and/or biopredictive dissolution methods to support biowaiver extensions 103 
and enabling extrapolation to special populations (e.g., paediatrics). Although the current PBPK 104 
regulatory guidelines still mainly focus on the prediction of drug-drug interactions (DDIs),(European 105 
Medicines Agency (EMA), 2018a; U.S.FDA Center for Drug Evaluation and Research (CDER), 2018a) the 106 
integration of translational biopharmaceutical modeling and dissolution testing has been attracting 107 
increased attention from leading pharmaceutical industries as well as regulatory bodies and over the 108 
last few years, the regulatory impact of mechanistic absorption modeling has significantly 109 
increased.(Babiskin and Zhang, 2015; Heimbach et al., 2019; Pepin et al., 2016; Zhang et al., 2017) 110 
Establishing bioequivalence (BE) has been a critical component of and remains a challenge during 111 
development of both new drug and generic products. In the context of quality by design (QbD) and the 112 
biopharmaceutics risk assessment roadmap (BioRAM),(Selen et al., 2014),(Dickinson et al., 2008) the 113 
importance of linking in vitro with in vivo data bi-directionally has received greater emphasis. 114 
Accordingly, virtual bioequivalence (VBE) can serve as a powerful tool to set clinically relevant 115 
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specifications and predict anticipated clinical outcomes in healthy, patient and special-patient (e.g., 116 
paediatrics and/ or co-administration of PPIs) populations. To accurately predict the in vivo 117 
performance of a drug product through clinical trial simulation, a certain set of conditions needs to be 118 
met. This includes integration of biorelevant in vitro data into the simulation model as well as 119 
mechanistic absorption modelling, disposition/elimination components and consideration of 120 
physiological and physicochemical interactions with the formulation. After developing the mechanistic 121 
absorption PBPK model, it must be verified via learn/ confirm cycles which rely on evaluation against 122 
observed clinical data. Such models can then be used to predict the population pharmacokinetic 123 
variability of the test drug/ formulation and therefore enable assessment of bioequivalence risks via 124 
virtual trials simulations.(Pathak et al., 1997)  125 
The ability of PBPK to account for between-subject (BS), within-subject (WS) and inter-occasion 126 
variability (IOV) is crucial to the accuracy and the applicability of VBE results. Although the current 127 
techniques can address the between-subject variability reasonably well, progress still needs to be 128 
made in the area of estimating inter-occasion variability. Two independent modeling strategies to 129 
incorporate IOV in VBE studies have been implemented in the literature: a) a priori estimated random 130 
error terms in replicate clinical study are added to the PK parameters, or, more mechanistically, b) the 131 
IOV is integrated into the system parameters and propagated in simulations.(Wedagedera et al., 2017) 132 
In this study, an in vitro-in vivo-in silico workflow to establish VBE and clinically relevant dissolution 133 
specifications is proposed. Naproxen and its sodium salt was chosen as the case example. Naproxen is 134 
a weakly acidic (pKa ≈4.4) non-steroid anti-inflammatory (NSAID) agent. It is a biopharmaceutical 135 
classification system (BCS) class II weak acid with poor solubility in the fasted stomach but freely 136 
soluble in the intestinal environment and has a high permeability, similar to ibuprofen and 137 
diclofenac.(Cristofoletti et al., 2013; Cristofoletti and Dressman, 2016; Kambayashi et al., 2013) Since 138 
the absorption of such compounds is usually complete, they have been identified as offering 139 
opportunities for a potential BCS-based biowaiver extension.(Cristofoletti and Dressman, 2016; Tubic-140 
Grozdanis et al., 2008; Yazdanian et al., 2004) The free acid (Naprosyn®) and the sodium salt 141 
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(Anaprox®) forms are administered orally as immediate release (IR) tablets. The purpose of this article 142 
is to characterize the in vitro dissolution behavior of naproxen pure API and formulations, integrate 143 
mechanistic absorption modeling with population-based PBPK, design a safe space and, last but not 144 
least, set clinically relevant dissolution specifications through VBE trials. The possibility/ risk of granting 145 
BCS-biowaiver for naproxen products is also investigated. 146 
 147 
2 Material and Methods 148 
 149 
2.1 Chemicals and reagents 150 
 151 
Naproxen (lot #SLBV2253) and naproxen sodium (lot #MKCD6021) pure active pharmaceutical 152 
ingredient (API) were purchased commercially from Sigma-Aldrich Co., LLC. (St. Louis, MO). Naproxen 153 
tablets (500 mg Naprosyn®, lot 70662; Minerva Pharmaceutical Inc., Athens, Greece) and naproxen 154 
sodium tablets (550 mg Anaprox®, lot 70466; Minerva Pharmaceutical Inc., Athens, Greece) were 155 
commercially purchased from the Greek market. Fasted state simulated gastric fluid (FaSSGF)/fasted 156 
state simulated intestinal fluid (FaSSIF V1)/fed state simulated intestinal fluid (FeSSIF V1) powder (lot 157 
01-1512-05NP), FeSSIF V2 powder (lot 03-1610-02) and FaSSIF V3 powder (lot PHA S 1306023) were 158 
kindly donated from Biorelevant.com Ltd., (Surrey, UK). Acetonitrile (lot 18A101551) and water (lot 159 
17B174006) of HPLC-grade were from VWR Chemicals (Leuven, Belgium). Sodium hydroxide pellets 160 
(lot 14A100027), sodium chloride (lot 17I074122), sodium acetate (lot 14B240013), hydrochloric acid 161 
37% (lot 10L060526), orthophosphoric acid 85% (lot 12K210017) and glacial acetic acid 100% (lot 162 
12B220508) were commercially obtained from VWR Chemicals (Leuven, Belgium). Sodium dihydrogen 163 
phosphate dehydrate (lot K93701642712), maleic acid (lot 57118880544) and citric acid (lot 164 
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K91221207425) were commercially purchased from Merck KGaA (Darmstadt, Germany). Pepsin from 165 
pocrine gastric mucosa 19.6% and Lipofundin® MCT/LCT 20% were from Sigma-Aldrich Co., LLC. (St. 166 
Louis, MO) and B. Braun Melsungen AG (Melsungen, Germany), respectively. 167 
 168 
2.2 In vitro solubility experiments 169 
 170 
The solubility of naproxen and its sodium salt was investigated in various selected aqueous and 171 
biorelevant dissolution media using the Uniprep™ system (Whatman®, Piscataway, NJ, USA). All 172 
aqueous buffers were prepared according to the European Pharmacopoeia, while the biorelevant 173 
media were prepared according to Markopoulos et al. and Fuchs et al.(Fuchs et al., 2015; Markopoulos 174 
et al., 2015) The composition and physicochemical characteristics of the fasted and fed state 175 
biorelevant media used in this study are summarized in Table 1. An excess amount of API was added 176 
to 3 mL of dissolution medium and the samples were incubated for 24 h at 37°C on an orbital mixer. 177 
The samples were then filtered through the 0.45 μm PTFE filter integrated in the Uniprep™ system. 178 
The filtrate was immediately diluted with mobile phase and analyzed by high-performance liquid 179 
chromatography (HPLC) (see section 2.5). All measurements were performed at least in triplicate (n≥3). 180 
 181 
Table 1: Composition and physicochemical characteristics of biorelevant media in the fasted and fed states. 182 
 183 
2.3 In vitro dissolution tests 184 
 185 
All dissolution tests were performed using calibrated USP II (paddle) apparatus (Erweka DT 80, 186 
Heusenstamm, Germany) at 37±0.4°C. Each vessel contained 500 mL of fresh, pre-warmed medium 187 
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and the rotational speed was set at 75 rpm. Samples were withdrawn at 2.5, 5, 10, 15, 20, 30, 45, 60, 188 
90 and 120 minutes via a 5 mL glass syringe connected to a stainless-steel cannula containing a 10 μm 189 
polyethylene cannula filter. Immediately thereafter, the sample was filtered through a 0.45 μm PTFE 190 
filter (ReZist™ 30, GE Healthcare UK Ltd., Buckinghamshire, UK), discarding the first 2 mL. The filtrate 191 
was immediately diluted with mobile phase and analyzed by HPLC-UV (see section 2.5). The removal 192 
of 5 mL at each sampling time was taken into account in the calculation of the percentage dissolved. 193 
All experiments were performed at least in triplicate (n≥3) and the final pH in the vessel was recorded.  194 
 195 
2.4 Two-stage dissolution tests 196 
 197 
Since the conventional one-stage USP II dissolution test does not include a gastric compartment to 198 
account for disintegration of the dosage form in the stomach, differences in the disintegration time 199 
between non-coated (i.e. 500 mg Naprosyn®) and simple coated formulation (i.e. 550 mg Anaprox®) 200 
might bias the interpretation of the biorelevant in vitro dissolution behavior with respect to the in vivo 201 
performance. Therefore, to investigate the disintegration effect on the in vitro performance of 202 
naproxen/ naproxen sodium formulations, a two-stage dissolution test for FaSSIF V3 was developed 203 
based on the publication by Mann et al. (Mann et al., 2017) 204 
The dosage form was initially exposed to 250 mL of FaSSGF Level III and samples were removed at 5, 205 
10, 15, 20, 30 minutes and treated as described in section 2.3.  After the withdrawal of the last sample, 206 
6.8 mL of sodium hydroxide 1M and immediately thereafter 250 mL of FaSSIF V3 concentrate pH=6.7 207 
(double concentration of all the constituents, apart from sodium hydroxide) were added to the vessel. 208 
Instead of increasing the pH of the intestinal medium concentrate to counterbalance the acidic pH of 209 
the stomach medium as described in the original study,(Mann et al., 2017) sodium hydroxide was 210 
added first, but almost simultaneously, with the FaSSIF V3 concentrate. This was done to avoid using 211 
a very high pH in the FaSSIF V3 concentrate. After addition of sodium hydroxide and concentrated 212 
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FaSSIF V3, further samples were removed at 32.5, 35, 40, 45, 50, 60 and 90 minutes. The two-stage 213 
experiments were performed using calibrated USP II (paddle) apparatus (Erweka DT 80, Heusenstamm, 214 
Germany) at 37±0.4°C and the samples were analyzed by HPLC-UV (see section 2.5). All experiments 215 
were performed at least in triplicate (n≥3) and the final pH in the vessel was recorded. 216 
 217 
 218 
2.5 Quantitative Analysis of Samples 219 
 220 
Samples obtained from solubility and dissolution experiments were first filtered through a 0.45 μm 221 
PTFE filter (ReZist™ 30 syringe filter or Uniprep™; Whatman®, Piscataway, NJ, USA) and subsequently, 222 
after appropriate dilution with mobile phase, they were analyzed by HPLC-UV (Hitachi Chromaster; 223 
Hitachi Ltd., Tokyo, Japan or Spectra System HPLC, ThermoQuest Inc., San Jose, USA). A BDS Hypersil 224 
C18, 5 μm, 150 x 4.6 mm (Thermo Scientific) analytical column combined with a pre-column (BDS 225 
Hypersil C-18, 3μm, 10 x 4mm) was used. The mobile phase consisted of 20 mM NaH2PO4 buffer 226 
adjusted to pH=3.0 and acetonitrile (60:40 % v/v). The detection wavelength was set at 273 nm, the 227 
flow rate at 1.2 mL/min and the injection volume at 20 μL. Using this method, the retention time was 228 
approximately 7.3 minutes. The limit of detection (LOD) and quantification (LOQ) were 0.03 and 0.1 229 
μg/mL, respectively. 230 
2.6 Model-based analysis of in vitro solubility data 231 
 232 
An experimental estimate of the naproxen pKa was obtained by fitting the Henderson-Hasselbalch 233 
equation (Eq. 1) to the mean aqueous equilibrium solubility (𝑆𝑖) values using the SIVA Toolkit® (n=6; 234 
all aqueous buffers). As intrinsic solubility (𝑆0), the lowest reported value in buffers was used. The pKa 235 
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was then compared with values available in the literature to confirm the validity of the aqueous 236 
solubility parameter estimates. 237 
 𝑆𝑖 = 𝑆0 ∙ (10 
𝑝𝐻−𝑝𝐾𝑎) (1) 
 238 
The impact of bile salt concentration ([𝐵𝑆]) and subsequent formation of micelles on the solubility of 239 
naproxen was investigated. This was done by mechanistically modelling the mean solubility values in 240 
fasted state biorelevant media (n=3), accounting also for the relative proportions of naproxen 241 
solubilized in the aqueous versus the micelle phases, using the total solubility (𝑆(𝐵𝑆)𝑇𝑜𝑡) equation (Eq. 242 
2) in SIVA Toolkit® version 3.0 (SIVA; Certara, Simcyp Division; Sheffield, UK). Estimates of the logarithm 243 
of the micelle-water partition coefficient for the neutral (𝐾𝑚:𝑤,𝑢𝑛𝑖𝑜𝑛𝑖𝑧𝑒𝑑) and ionized drug 244 
(𝐾𝑚:𝑤,𝑖𝑜𝑛𝑖𝑧𝑒𝑑) were obtained to quantify the micelle-mediated solubility. 245 
 
𝑆(𝐵𝑆)𝑇𝑜𝑡 = ( [𝐵𝑆] ∙
𝑆0
𝐶𝐻2𝑂
∙ 𝐾𝑚:𝑤,𝑢𝑛𝑖𝑜𝑛𝑖𝑧𝑒𝑑 +  𝑆0) + (  [𝐵𝑆] ∙
𝑆𝑖
𝐶𝐻2𝑂
∙ 𝐾𝑚:𝑤,𝑖𝑜𝑛𝑖𝑧𝑒𝑑 +  𝑆𝑖)  
 
(2) 
Where 𝐶𝐻2𝑂 stands for the concentration of water. 246 
Estimation of the relevant parameters was performed using the Nelder-Mead algorithm and weighting 247 
by the reciprocal of the predicted values was chosen. After model verification, all obtained estimates 248 
were used as input parameters for the development of the physiologically-based pharmacokinetic 249 
model (PBPK) model (see section 2.9) 250 
2.7 Model-based analysis of in vitro dissolution data 251 
 252 
Once confidence in the estimation of solubility-related parameters was established, further model-253 
based analysis of the in vitro dissolution data obtained from both the one and two-stage tests was 254 
performed within the serial dilution module of the SIVA Toolkit® (SIVA 3.0). The dissolution rate of 255 
spherical particles under sink and non-sink conditions within SIVA is described by an extension of the 256 
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diffusion layer model (DLM) developed by Wang and Flanagan. (Eq. 3) (Wang and Flanagan, 2002, 257 
1999) 258 
 𝐷𝑅(𝑡) = −𝑁 ∙ 𝑆𝐷𝐿𝑀 ∙
𝐷𝑒𝑓𝑓
ℎ𝑒𝑓𝑓(𝑡)
∙ 4𝜋 ∙ 𝛼(𝑡) ∙ (𝛼(𝑡) + ℎ𝑒𝑓𝑓(𝑡)) ∙ (𝑆𝑠𝑢𝑟𝑓𝑎𝑐𝑒(𝑡) − 𝐶𝑏𝑢𝑙𝑘(𝑡)) (3) 
 259 
where 𝐷𝑅(𝑡) is the dissolution rate at time t; N is the number of particles in a given particle size bin; 260 
𝑆𝐷𝐿𝑀 is a lumped, empirical, correction scalar without regard to the mechanistic origin of the required 261 
correction to the DLM. The estimated SDLM values obtained with SIVA can be applied to the Simcyp 262 
PBPK simulator to reflect differences between media or formulations; 𝐷𝑒𝑓𝑓 is the effective diffusion 263 
coefficient; ℎ𝑒𝑓𝑓(𝑡) and 𝛼(𝑡) represent the thickness of the hydrodynamic boundary layer and the 264 
particle radius at time t respectively; 𝑆𝑠𝑢𝑟𝑓𝑎𝑐𝑒(𝑡) corresponds to the saturation solubility at the particle 265 
surface (which may be different to the bulk fluid solubility as discussed below); and 𝐶𝑏𝑢𝑙𝑘(𝑡) is the 266 
concentration of dissolved drug in bulk solution at time t.  267 
The ℎ𝑒𝑓𝑓(𝑡) was calculated by the fluid dynamics sub-model, which enables the hydrodynamic 268 
conditions to be described according to local conditions and stirring rate. Fluid dynamics-based ℎ𝑒𝑓𝑓(𝑡) 269 
is the recommended option for describing the hydrodynamics, as it permits a more rational translation 270 
of estimated parameters such as the 𝑆𝐷𝐿𝑀  to in vivo conditions, in which the hydrodynamics are 271 
usually quite different to in vitro experiments.  272 
The local pH at the particle surface of ionisable drugs can significantly affect the 𝑆𝑠𝑢𝑟𝑓𝑎𝑐𝑒 and 273 
consequently the dissolution rate.(K. G. Mooney et al., 1981; K.G. Mooney et al., 1981a, 1981b; Ozturk 274 
et al., 1988; Serajuddin and Jarowski, 1985; Sheng et al., 2009) Since in the in vitro dissolution media 275 
have a somewhat higher buffer capacity than the intestinal fluids, the self-buffering effect at the solid 276 
surface can be underestimated. For this reason, the surface pH was calculated and directly input into 277 
SIVA. The calculation of the surface pH was based on the model proposed by Mooney et al.(K.G. 278 
Mooney et al., 1981a), which assumes that dissolution is the result of both chemical reaction between 279 
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the conjugate base of the buffer species and the hydrogen cations released from the dissolving drug 280 
(in this case naproxen free acid (NPX-H)) the liquid-solid interface and the diffusion of the dissolved 281 
particles to the bulk. This model  is very similar to the quasi-equilibrium model published by Ozturk et 282 
al.(Ozturk et al., 1988), a derivation of which is implemented in SIVA as the default option for surface 283 
pH calculations. 284 
By fitting the DLM model to the observed dissolution data, accurate 𝑆𝐷𝐿𝑀 estimates for each 285 
dissolution and two-stage test were obtained. In the case of two-stage testing, the gastric and 286 
intestinal profiles were treated separately. Under fasted state intestinal conditions, naproxen is freely 287 
soluble and therefore in vitro dissolution is not expected to be solubility limited. In that case, 288 
disintegration of the solid dosage form in the intestinal dissolution medium might be the rate-limiting 289 
step for the in vitro dissolution rate, especially in single dissolution experiments where the dosage 290 
form is directly exposed to the intestinal medium without any pre-treatment with gastric medium to 291 
account for disintegration in the stomach. In order to distinguish and model the relative impact of 292 
disintegration on the overall dissolution, the first-order disintegration option was activated in SIVA and 293 
used to obtain estimates of the first-order disintegration rate constant (𝑘𝑑) for these experiments. In 294 
the case of intestinal dissolution profiles generated after two-stage testing, the first-order 295 
disintegration option was deactivated since disintegration in the stomach had been already accounted 296 
for by the dissolution in the gastric medium. For dissolution experiments of the pure drug, the 297 
disintegration time was assumed to be negligible. 298 
Estimation of the relevant parameters was performed using the Nelder-Mead algorithm and equal 299 
weighting was applied. The various estimated 𝑆𝐷𝐿𝑀 and 𝑘𝑑 values were implemented in the Simcyp® 300 
Simulator (V18.1; Certara, Sheffield, UK) to simulate various in vivo dissolution scenarios for the 301 
formulations under study and to generate in vitro-in vivo extrapolation relationships. These are 302 
necessary to predict the formulation or pure drug in vivo performance using PBPK modelling. 303 
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2.8 In vivo studies 304 
 305 
Seven clinical trials published in the open literature were used in support of the development and 306 
verification of the PBPK model for naproxen. Six studies were performed after oral administration of 307 
single-dose of naproxen or its sodium salt at different dose levels in the fasted state. Data after 308 
intravenous administration were obtained from Runkel et al.(Runkel et al., 1973, 1972a, 1972b)  309 
The results of  bioavailability studies for the Naprosyn® formulation were published by Charles and 310 
Mogg(Charles and Mogg, 1994) and by Zhou et al.(Zhou et al., 1998) In the study by Charles and Mogg,  311 
sixteen Caucasian (12.5% females) healthy subjects with mean (SD) age of 22.1 (4.4) years old received 312 
one 500 mg Naprosyn® tablet with 100 mL water at 8:00 a.m. after an overnight fast. All individuals 313 
were within 20% of their ideal body weight for height and gender with a mean (SD) weight and height 314 
of 67.6 (8.3) kg and 175.7 (9.0) cm, respectively. In the study by Zhou et al., ten Chinese healthy male 315 
volunteers (with age and body weight ranging from 19-38 year and 51-74 kg respectively) received two 316 
250 mg Naprosyn® tablets with 200 mL water at 8 a.m. after an overnight fast. 317 
Regarding the Anaprox® formulation, a bioavailability study by Haberer et al.(Haberer et al., 2010) and 318 
a bioequivalence (BE) study by Setiawati et al.(Setiawati et al., 2009) have been reported in the 319 
literature. Using the same study design (two-treatments protocol), Haberer et al. tested the 320 
bioavailability of a tablet of 550 mg Anaprox® as well as of 500 mg of naproxen sodium, with the 321 
intention of incorporating this dose in a fixed dose combination tablet with sumatriptan. A tablet of 322 
550 mg Anaprox® (treatment A) and of 500 mg of naproxen sodium (treatment B) were administered 323 
after an overnight fast to 8 and 16 healthy non-smoker volunteers, respectively. The proportion of 324 
females in the study was 63% and subjects had a mean (SD) age of 44.3 (8.5) years and a mean body 325 
weight of 71.44 (12.3) kilograms. In the study by Setiawati et al., twenty-six healthy volunteers (15% 326 
females), aged 19 to 46 years and with body mass index (BMI) 18-23, were administered a tablet 327 
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containing 550 mg naproxen sodium with 200 mL of water in a sitting position at 07:00 a.m. after an 328 
overnight fast.  329 
To investigate the bioavailability of naproxen free acid, Rao et al. administered 500 mg of pure drug 330 
powder filled in hard capsules together with a glass of water to twelve Indian healthy male volunteers, 331 
aged between 18 and 22 years, who had fasted overnight.(Rao et al., 1993) In all studies, no 332 
concomitant administration of any other drugs was permitted for at least 1 week before the study and 333 
food was withheld until 3 hours post-dose.  334 
All available demographic data from the aforementioned clinical studies were used to simulate the 335 
clinical trials and are summarized in Table 2. Since no pharmacokinetic differences due to race have 336 
been identified to date, all individuals were treated the same in terms of ethnicity for modeling 337 
purposes.  338 
 339 
Table 2: Mean (SD) demographic data of in vivo studies used for the development and verification of the PBPK model. (HV= healthy volunteers) 340 
 341 
 342 
2.9 Development of the middle-out PBPK model and selection of in silico input 343 
parameters 344 
 345 
PBPK modeling and simulations were performed using the Simcyp® Simulator (V18.1; Certara, 346 
Sheffield, UK). The naproxen PBPK model was developed by implementing a stepwise sequential 347 
modeling strategy, in line with previously published literature and the regulatory guidelines.(European 348 
Medicines Agency (EMA), 2018b; Ke et al., 2016; Kuepfer et al., 2016; Shebley et al., 2018; U.S.FDA 349 
Center for Drug Evaluation and Research (CDER), 2018b; Zhao et al., 2012)  Initially, an intravenous (IV) 350 
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model was set up and, after optimizing the distribution/elimination parameters, it was adapted to 351 
mechanistically describe oral absorption. The compound file was also informed with physicochemical 352 
parameters including molecular weight (MW), octanol:water partition coefficient (logPo:w), fraction 353 
unbound in plasma (fu) and blood to plasma ratio (B:P) obtained from the literature.(Bergström et al., 354 
2014; Brown et al., 2007; Davies and Anderson, 1997; Lin et al., 1987; Paixão et al., 2012; Pérez et al., 355 
2004; Zhao et al., 2001)  356 
 357 
2.9.1 Intravenous (IV) model 358 
 359 
Since the volume of distribution reported in the literature for naproxen usually lies between 0.05-0.2 360 
L/kg (similar to the plasma water volume),(Awni et al., 1995; Franssen et al., 1986; Gøtzsche et al., 361 
1988; Niazi et al., 1996; Upton et al., 1984; Van den Ouweland et al., 1988; Vree et al., 1993) the 362 
minimal PBPK (mPBPK) with a single adjusting compartment (SAC) was chosen as the distribution 363 
model. The mPBPK is a “lumped” PBPK model in which the SAC represents all tissues excluding liver 364 
and portal vein. Use of the SAC requires prior fitting to observed clinical data using the Simcyp® 365 
parameter estimation (PE) module. Implementing a “middle-out” strategy, the post-absorptive 366 
variables, i.e. the parameter values for volume of distribution at steady-state (𝑉𝑠𝑠), apparent SAC 367 
volume (𝑉𝑠𝑎𝑐), inter-compartmental (𝑄𝑠𝑎𝑐) and in vivo IV clearance (𝐶𝐿𝐼𝑉) were estimated using the 368 
PE module after simultaneous fitting of the mPBPK model to the observed intravenous data.(Runkel et 369 
al., 1973, 1972a, 1972b) The estimation was weighted by the number of individuals in the reported 370 
study and the resulting parameters were then compared with values reported in the literature. 371 




For mechanistic absorption modeling the advanced dissolution absorption and metabolism (ADAM) 374 
model,(Jamei et al., 2009; S. Darwich et al., 2010) in which the gastrointestinal tract (GIT) is divided 375 
into 9 anatomically distinct segments starting from stomach through small intestine to the colon, was 376 
used. It was assumed that no drug absorption in the stomach occurred. The effective permeability 377 
(Peff,man) value in humans was obtained from the literature,(Lennernas et al., 1995) whereas for 𝑆0, 378 
𝑙𝑜𝑔𝐾𝑚:𝑤,𝑢𝑛𝑖𝑜𝑛𝑖𝑧𝑒𝑑, 𝑙𝑜𝑔𝐾𝑚:𝑤,𝑖𝑜𝑛𝑖𝑧𝑒𝑑  the estimates from model-based analysis of the in vitro solubility 379 
data were implemented (see section 2.7). Default settings of the software for luminal blood flow, fluid 380 
volume, bile salt content, segmental pH, metabolic activity and small intestinal residence time were 381 
used. The mean gastric emptying time (GET) in the fasted state was set to 0.25 h (matching the built-382 
in ‘segregated transit time’ model value instead of the default value of 0.4 h used in the ‘global’ transit 383 
time model), as suggested by human clinical data and several authors.(Cristofoletti et al., 2016; Hens 384 
et al., 2014; Paixão et al., 2018; Psachoulias et al., 2011) All relevant input parameters for the 385 
development of the PBPK models and simulations are summarized in Table 3. 386 
Table 3: Input parameters for naproxen PBPK model development and simulations 387 
 388 
2.10 Verification of PBPK model and Clinical Trial simulations 389 
 390 
The performance of the developed PBPK model was verified by simulation of several clinical studies 391 
after oral administration and by comparison with the mean observed pharmacokinetic profiles already 392 
available in the literature.(Charles and Mogg, 1994; Haberer et al., 2010; Rao et al., 1993; Setiawati et 393 
al., 2009; Zhou et al., 1998) Virtual populations were selected to closely match the enrolled individuals 394 
in the respective in vivo clinical trials with respect to sample size, ethnicity, gender ratio, and age and 395 
weight range. Reported volumes of concomitant liquid intake, dosage form type and sampling 396 
schedule were also included in the study design.  397 
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Using an in vitro-in vivo extrapolation (IVIVE) approach, the various DLM scalar estimates, (see sections 398 
2.7, 3.5) obtained by model-based analysis of the in vitro dissolution data with the diffusion layer 399 
model were input to best capture different in vivo dissolution scenarios. Further, to investigate the 400 
effect of in vivo dissolution of multiple formulations and under various conditions on the overall in vivo 401 
performance, the same DLM scalar estimates from in vitro dissolution data for each case were 402 
implemented to simulate the aforementioned clinical studies. Every in vivo dissolution scenario was 403 
evaluated by simulating of 10 trials, each with 10 subjects each (Σ=100). All virtual clinical trials were 404 
matched in terms of demographic data (e.g. gender ratio, age & weight range) as closely as possible to 405 
the reported studies. 406 
2.11 Parameter Sensitivity Analysis (PSA) 407 
 408 
Once confidence in the PBPK model performance was established, parameter sensitivity analysis (PSA) 409 
was conducted to identify the absorption rate limiting steps and their impact on in vivo performance 410 
(e.g., Cmax, tmax, AUC). Variation of one or two parameters at a time over a physiologically realistic range 411 
of values was applied for gastric emptying time (GET) and the DLM scalar.  412 
 413 
2.12 Virtual Bioequivalence (VBE) Trials 414 
 415 
The virtual bioequivalence (VBE) trials were designed as fully replicated, two-sequence, two-416 
treatment, two-period, crossover studies. In virtual BE studies between the hypothetical test and 417 
reference formulations, PK profiles for a total of 120 healthy adult volunteers (12 subjects in each of 418 
10 trials) for each treatment were generated. The existing default coefficients of variation (%CV) - i.e., 419 
between subject (BS) variability of the physiological parameters stored in the Simcyp® simulator 420 
database for the North European Caucasian healthy adult volunteers’ population were applied for each 421 
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parameter. As an integral part of within-subject (WS) variability, inter-occasion variability (IOV) 422 
significantly contributes to the overall population variability and therefore it should be accounted for 423 
by the PBPK models. To model IOV, a CV of 30% was set, according to the literature and unpublished 424 
data from C. Reppas.(Fruehauf et al., 2007; Grimm et al., 2018; Lartigue et al., 1994; Petring and Flachs, 425 
1990)  IOV was added through the VBE module (V1.0) of Simcyp® simulator to the mean GET, pH of 426 
fasted stomach, pH and bile salts concentration of fasted duodenum, jejunum I and II segments and 427 
mechanistically propagated in the simulations. The IOV was intentionally set to the somewhat 428 
exaggerated value of 30% for all the relevant parameters to further challenge the establishment of 429 
bioequivalence. In each trial, a pre-specified number of randomly simulated individuals (n=12) were 430 
generated for each formulation (reference and test). The relevant PK metrics (Cmax, tmax, AUC) for each 431 
subject were calculated.  The VBE trials were interpreted as crossover studies and average BE (ABE) 432 
was assessed using Phoenix® WinNonlin (v8.1; Certara; Princeton, NJ, USA) for each relevant PK metric. 433 
In a best-and worst-case scenario the hypothetical reference and test formulations were assumed to 434 
have in vivo dissolution in the virtual individuals corresponding to the highest and lowest estimated 435 
DLM scalar value, respectively, resulting from the model-based analysis of the in vitro dissolution data. 436 
2.13 Data Analysis and Model Diagnostics 437 
 438 
The solubility and dissolution data are presented as the arithmetic mean with standard deviations. 439 
Model-based analysis of the in vitro data in SIVA® Toolkit was performed with either the Nelder Mead 440 
or the hybrid algorithm (genetic algorithm coupled to Nelder Mead) with a 5th order Runge-Kutta or 441 
Livermore solver. Different weighting schemes were tested and the goodness of fit was assessed by 442 
the Akaike (AIC, AICc) and Bayesian (BIC) information criteria as well as the coefficient of determination 443 
(R squared). All PK profiles obtained from the literature were digitalized with the WebPlotDigitizer 444 
(version 4.1; PLOTCON; Oakland, USA). The estimation of the post-absorptive parameters within the 445 
PE module of the Simcyp® Simulator was performed with the Maximum Likelihood estimation method. 446 
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The prediction accuracy of the simulated plasma profiles was evaluated with the average fold error 447 
(AFE) and absolute average fold error (AAFE) (see Equations 4,5). 448 







    (4) 
 449 







  (5) 
 450 
 451 
where n is the number of time points at which the concentration was determined and 𝑝𝑟𝑒𝑑𝑡, 𝑜𝑏𝑠𝑡 are 452 
the predicted and observed concentrations at a given time point t respectively. 𝐴𝐹𝐸 deviation from 453 
unity is an indication of over- (𝐴𝐹𝐸 > 1) or under-prediction (𝐴𝐹𝐸 < 1) of the observed data, 454 
whereas 𝐴𝐴𝐹𝐸 is a measure of the absolute error from the true value (or bias of the simulated profile). 455 
An 𝐴𝐴𝐹𝐸 ≤ 2 is considered to be a successful prediction.(Obach et al., 1997; Poulin and Theil, 2009) 456 
Statistical analysis (including 95% CI) and VBE trials were performed with Simcyp® (V18.1; Certara, 457 
Sheffield, UK) and Phoenix® WinNonlin (v8.1; Certara; Princeton, NJ, USA). Data post-processing and 458 
plotting were performed with MATLAB® 2018a (Mathworks Inc.; Natick, MA, USA) and R® (version 459 
3.5.1). 460 




3 Results 463 
3.1 In vitro solubility  464 
 465 
3.1.1 Aqueous Buffers 466 
 467 
Table 4 summarizes the equilibrium solubility values in various aqueous media of different pH. In the 468 
case of the free acid, the final pHbulk differed significantly from the initial pH values due to the self-469 
buffering effect. This behavior was not observed for the sodium salt, where the pH difference was 470 
equal or less to 0.1 pH unit. The higher solubility of the sodium salt compared to the free acid, 471 
especially in the intestinal pH media, is attributed to the difference in the final pH measured, keeping 472 
in mind that in this pH range the solubility increases exponentially with pH increase. Since naproxen is 473 
a weakly acidic compound, its pH-solubility profile is described by two regions: a) pH < pHmax, where 474 
the excess solid phase in equilibrium with the saturated solution consists of the unionized form and b) 475 
pH > pHmax, where the equilibrium species are exclusively in the ionized form.(Avdeef, 2007) Hence, 476 
unless self-association of solute molecules occurs, identical pH-solubility profiles at equilibrium are 477 
expected regardless of the starting material (free acid or salt), as shown in Figure 1. The experimental 478 
values were plotted as a pH-solubility profile and compared to values reported in the literature, 479 







Table 4: Mean (± SD) equilibrium solubility in aqueous media at 37°C for 24h (Uniprep® method). 485 
 486 
Figure 1: Naproxen (squares) and naproxen sodium (triangles) experimental mean equilibrium solubility values (24 h at 37°C) 487 
plotted against respective literature values (24 h at 25°C) in a pH-solubility profile. The in vitro solubility experiments were 488 
performed with the Uniprep® method described in section 2.2. The experimental results are in agreement with the literature 489 
values (24 h at 25°C). The literature values were obtained from Avdeef et al. (Ref. 75); Chowhan et al. (Ref. 77) 490 
 491 
3.1.2 Biorelevant media 492 
 493 
The solubility was additionally investigated in selected Level II fasted and fed state biorelevant media 494 
(see Table 5).(Markopoulos et al., 2015) Similar to the solubility of the free acid in phosphate buffers, 495 
a considerable decrease in the final pHbulk was observed in fasted state biorelevant media. In fact, the 496 
reduction is even more pronounced in the fasted state biorelevant media due to their lower buffer 497 
capacity (5.6 mmol/L/ΔpH in FaSSIF V3 versus 18.5 mmol/L/ΔpH in European Pharmacopoeia 498 
phosphate buffers).(Fuchs et al., 2015) Comparison of solubilities in compendial with those in 499 
biorelevant media shows that micelle-mediated solubilization has a substantial impact on the overall 500 
solubility of naproxen. Particularly in FaSSIF V1 Level II, the solubility of both free acid and sodium salt 501 
was increased by 25.8% and 51.8%, respectively, when compared to phosphate buffer (pH=6.5). 502 
Likewise, in media simulating the fed state, such as FeSSIF V1 Level II, a 2.4-fold increase in the 503 
solubility of the free acid and a 2.1-fold increase for the salt form were observed, in comparison to the 504 
respective medium without surfactants. 505 
 506 




3.2 Modeling of in vitro solubility  509 
 510 
Table 6 summarizes the parameter estimates (95% CI) obtained by model-based analysis of the in vitro 511 
solubility data in compendial and biorelevant media, as described in section 2.6. The pKa was 512 
determined to be 4.43, which agrees with values reported in the literature (4.15-4.5). (Avdeef, 2007; 513 
Chowhan, 1978; Davies and Anderson, 1997; McNamara and Amidon, 1986; Sheng et al., 2009)  By 514 
estimating the micelle-water partition coefficients for both neutral and ionized species using the 515 
biorelevant solubilities, we were able to quantify the effect of physiologically relevant surfactants on 516 
the overall solubility of naproxen. These values were utilized within the Simcyp® Simulator to simulate 517 
the luminal conditions and the in vivo dissolution behavior, accounting at the same time for any inter-518 
subject variability regarding bile salt-mediated solubilization in the virtual population. Therefore, 519 
implementation of logKm:w neutral and ion in the PBPK model allowed for mechanistic prediction of the 520 
in vivo luminal dissolution, which would not be possible if only mean solubility values had been used. 521 
 522 
Table 6: Parameter estimates (95% CI) resulting from the model-based analysis of in vitro solubility data in aqueous as well as 523 
biorelevant media. The pka was estimated from the aqueous solubility values, whereas for the micelle-water partition 524 
coefficients (logKm:w neutral, ion) estimation, biorelevant solubilities were used. The accuracy of the predictions was evaluated 525 
with the R squared. 526 
 527 
3.3 In vitro dissolution tests 528 
 529 




Mean percentage dissolved (± SD) over time in compendial and fasted state biorelevant media for the 532 
pure API of naproxen and its sodium salt are presented in Figure 2 and Figure 3, respectively. All 533 
dissolution experiments were performed as described in section 2.3.  534 
For the free acid, dissolution in FaSSIF V3 Level II and in Ph. Eur. phosphate buffer pH=6.8 was very 535 
rapid (>85% within 5 minutes in FaSSIF V3) and rapid (>85% within 30 minutes in phosphate buffer). 536 
On the other hand, the dissolution in FaSSIF V3 Level I (i.e. without bile components) was much slower 537 
with 85% dissolved reached only after 60 minutes. The observed differences in in vitro dissolution 538 
behavior is attributed to differences in buffer capacity (FaSSIF V3 Level I and II vs. phosphate buffer) 539 
and solubilization capacity (FaSSIF V3 Level II vs. Level I) of the tested media, whereas the difference 540 
of 0.1 pH units between the initial pH of Ph. Eur. phosphate buffer pH=6.8 and FaSSIF V3 is assumed 541 
to have a negligible effect.  542 
Especially since dissolution was under non-sink conditions in this series of experiments, the dissolution 543 
rate in FaSSIF V3 Level I was significantly slower, due to its low buffer capacity (5.6 mmol/L/ΔpH), than 544 
in the compendial phosphate buffer (13.5 vs. 50 mM phosphate buffer). At higher total phosphate 545 
buffer concentration, i.e. in the compendial medium, the bulk (pHbulk) rather than the surface pH (pH0) 546 
drives solubility and dissolution.  By contrast, in the low buffer capacity FaSSIF V3 Level I medium the 547 
surface pH seems to control the dissolution rate and as a result the final pH is significantly altered (5.95 548 
in FaSSIF V3 Level I vs. 6.62 in Ph. Eur. phosphate buffer). The effect of buffer capacity on the overall 549 
dissolution behavior becomes much less prominent when bile salts are added to the medium, as shown 550 
in Figure 2. Furthermore, it is evident that the addition of the bile salt components in FaSSIF V3 Level 551 
II markedly enhances the dissolution rate. Although the main effect is likely through solubilization, 552 




For the sodium salt, these trends were not observed and dissolution was almost instantaneous (85% 555 
dissolved by the first sampling time at 2.5 min) in all tested media. This is attributed to the higher 556 
solubility as well as higher surface pH generated by the sodium salt of naproxen. 557 
 558 
 559 
Figure 3: In vitro dissolution (mean ± SD) of 550 mg naproxen sodium API powder in Ph. Eur. phosphate buffer (pH=6.8), FaSSIF 560 
V3 Levels I and II. USP paddle apparatus at 75 rpm and 500 mL of dissolution medium at 37°C were used in all experiments. 561 
The experiments were performed in triplicate. Horizontal dashed red line represents 85% dissolved. Most standard deviation 562 
bars lie within the symbols. 563 
 564 
3.3.2 Formulations 565 
 566 
The dissolution profiles in FaSSIF V3 Levels I and II along with the results for the “intestinal” part of the 567 
two-stage testing are presented for Naprosyn® and Anaprox® in Figure 4 and Figure 5, respectively. In 568 
all cases, and for both formulations, dissolution was very rapid under conditions simulating the upper 569 
small intestine, with 85% dissolved in less than 15 min. Interestingly, a mismatch between the 570 
dissolution results of the APIs and dosage forms was observed. For instance, dissolution of the free 571 
acid form of the API was much faster from the dosage form (Naprosyn®) than from the pure API in 572 
FaSSIF V3 Level I. However, the dissolution of naproxen free acid from Naprosyn® in FaSSIF V3 Level II 573 
was slightly slower than from the pure API. Furthermore, although dissolution of sodium salt API was 574 
virtually instantaneous in all media (85% dissolved within 2.5 min), 85% dissolution was reached only 575 
after 15 minutes during release from Anaprox®.  576 
Figure 2: In vitro dissolution (mean ± SD) of 500 mg naproxen free acid API powder in Ph. Eur. phosphate buffer (pH=6.8), 
Level I and II FaSSIF V3. USP paddle apparatus at 75 rpm and 500 mL of dissolution medium at 37°C were used in all 
experiments. The experiments were performed in triplicate. Horizontal dashed red line represents 85% dissolved. Most 
standard deviation bars lie within the symbols. 
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These findings suggested that the dissolution of the tablets under intestinal conditions was delayed 577 
due to slow disintegration, especially in the case of the sodium salt formulation. In order to account 578 
for disintegration in the stomach prior to exposure to the intestinal media, two-stage dissolution tests 579 
were subsequently performed, as described in section 2.4. Since the amount dissolved under gastric 580 
conditions was less than 2% in all cases (see Figure 6), only the “intestinal” profiles of the 2-stage tests 581 
are plotted and directly compared with the conventional dissolution profiles (Figure 4 and Figure 5). 582 
Pre-treatment in gastric media accelerated the dissolution rate (85% dissolved reached 5 min earlier) 583 
of the API from both the Naprosyn® formulation of the free acid (Figure 4) and the Anaprox® 584 
formulation of the sodium salt form  (Figure 5). Although in all cases dissolution would be considered 585 
very rapid, the disintegration effect was more prominent for Anaprox®, as shown also in Figure 6. A 586 
model-based analysis of the anticipated in vitro dissolution differences is presented in section 3.4. 587 
 588 
Figure 4: In vitro dissolution (mean ± SD) of Naprosyn® 500 mg in FaSSIF V3 Levels I and II (solid lines, filled squares and circles 589 
respectively). The intestinal profiles in FaSSIF V3 Levels I and II (after the pre-treatment with FaSSGF Levels I and III respectively) 590 
during two-stage test are also depicted (dotted lines, empty squares and circles, respectively). USP paddle apparatus at 75 591 
rpm and 500 mL of dissolution medium at 37°C were used in all experiments. The experiments were performed in triplicate. 592 
Horizontal dashed red line represents the 85% dissolved. Most standard deviation bars lie within the symbols 593 
 594 
Figure 5: In vitro dissolution (mean ± SD) of Anaprox® 550 mg in FaSSIF V3 Levels I and II (solid lines, filled squares and circles 595 
respectively). The intestinal profiles in FaSSIF V3 Levels I and II (after the pre-treatment with FaSSGF Levels I and III respectively) 596 
during two-stage test are also depicted (dotted lines, empty squares and circles, respectively). USP paddle apparatus at 75 597 
rpm and 500 mL of dissolution medium at 37°C were used in all experiments. The experiments were performed in triplicate. 598 









3.4 Modeling of in vitro dissolution  606 
 607 
Table 7 and Table 8 summarize the estimated DLM scalar values (95% CI) obtained by model-based 608 
analysis of the intestinal in vitro dissolution profiles using the SIVA Toolkit®. Each naproxen form (i.e. 609 
pure API and formulations of each of the free acid and sodium salt) was evaluated separately. The 610 
goodness of fit was visually inspected with residuals plots and assessed with the coefficient of 611 
determination (R2). As shown in Table 8, the first-order disintegration model without time-lag was 612 
applied only to those experiments where the formulations were not pre-exposed to gastric medium. 613 
Matching between two-stage and single dissolution, combined with the disintegration model, DLM 614 
estimates were obtained. These results indicate that the effect of disintegration can be properly 615 
accounted for using the methodology applied.  616 
The slowest and fastest dissolution rate of the acid form of the API observed in FaSSIF V3 Levels I and 617 
II, respectively, resulted in the lowest (0.0022) and highest (0.0810) estimated DLM values. Due to the 618 
virtually instantaneous dissolution of the sodium salt API in all media, the default DLM value of 1, 619 
without estimation, was utilized for the salt form (Table 7). The predicted dissolution profiles were in 620 
excellent agreement with the experimental profiles (R2 > 0.96). 621 
 622 
Figure 6: In vitro dissolution (mean ± SD) of Naprosyn® 500 mg (solid lines) and Anaprox® 550 mg (dashed lines) in FaSSGF 
Levels I and III  (filled circles and squares, respectively). USP paddle apparatus at 75 rpm and 250 mL of dissolution medium at 
37°C were used in all experiments. The experiments were performed in triplicate. Horizontal dashed red line represents the 
85% dissolved. Most standard deviation bars lie within the symbols. 
29 
 
Table 7 : Estimated DLM scalar values (95% CI) obtained from model-based analysis of in vitro dissolution in various media of 623 
naproxen free acid and sodium salt pure API powder. The goodness of fit between predicted and observed dissolution profiles 624 
was evaluated with the R squared (R2).  625 
 626 
Table 8: Estimated DLM scalar and first-order disintegration rate constant (kd) values (95% CI) obtained from model-based 627 
analysis of in vitro dissolution in various media of naproxen free acid (Naprosyn®) and sodium salt (Anaprox®) formulation. In 628 
case of dissolution without pre-treatment in a gastric medium, a first-order disintegration model was included. The goodness 629 
of fit between predicted and observed dissolution profiles was evaluated with the R squared (R2).  630 
 631 
3.5 PBPK model verification & clinical trial simulations 632 
 633 
The PBPK model of naproxen was developed and verified as described in sections 2.9 and 2.10, 634 
respectively. Post-absorptive parameters (CL, Vss, Vsac, Qsac) were estimated from intravenous data, 635 
whereas for dissolution-absorption the Diffusion layer model-ADAM was used. Different in vivo 636 
dissolution scenarios were simulated according to the DLM scalar values obtained by model-based 637 
analysis of in vitro biorelevant dissolution profiles of the tested naproxen forms. The simulated profiles 638 
were compared against observed data from human in vivo PK studies (see section 2.8). The generated 639 
virtual population closely matched the individuals enrolled in the respective in vivo studies in terms of 640 
ethnicity, gender ratio, and age and weight range. Volumes of concomitant liquid intake, dosage form 641 
type and sampling schedule were also taken into account for the virtual study design wherever 642 
available (see details in section 2.10). 643 
Table 9 summarizes all the simulations (10 trials by 10 individuals) performed for each in vivo 644 
dissolution scenario and the resulting mean in silico population pharmacokinetic (popPBPK) 645 
parameters for the virtual healthy adult population. Regardless of the anticipated differences in in vivo 646 
dissolution, as reflected by the various estimated DLM values, these results suggest that mean AUC 647 
remains almost constant, while more pronounced variations in Cmax and especially in tmax are observed. 648 
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Direct comparisons of the mean in silico and in vivo pharmacokinetic parameters show very good 649 
agreement between simulated and observed data (Table 9 and Table 10). In all cases, the average (AFE) 650 
and absolute average fold error (AAFE) lay between 0.90-1.16 and 1.07-1.04, reflecting successful PBPK 651 
model performance and excellent predictions of the observed plasma profiles.  652 
Figure 7 illustrates the mean simulated naproxen plasma-concentration time profiles and the 5th and 653 
95th percentiles of the virtual population for the two extreme DLM estimated values; i.e., 654 
DLMmin=0.0022 and DLMmax = 1. Note that these DLM values were extracted from the dissolution of 655 
the free acid and salt pure API forms, not the formulations, and were intentionally chosen as such in 656 
order to evaluate in vivo performance differences (if any) that could be detected under these extreme 657 
scenarios. As can be observed, the Cmax of the simulated plasma profile corresponding to 658 
administration of the very slowly dissolving hypothetical formulation was only slightly lower than the 659 
one resulting from the very fast dissolving hypothetical formulation. On the other hand, tmax was 660 
significantly prolonged. Interestingly, regardless of whether the worst or best case scenario was 661 
applied, the dissolution profiles predicted the observed range of PK profiles reasonably well (see also 662 
AFE and AAFE values). 663 
In order to further explore the impact of key parameters on the simulated plasma profiles, one-at-a-664 
time parameter sensitivity analysis (PSA) on the DLM scalar and GET in the fasted state was performed. 665 
GET and DLM were allowed to range from 0.1 to 2 hours and 0.001 to 0.1, respectively, while all other 666 
parameters in the model were kept constant. Figure 8 and Figure 9 show the mean simulated plasma 667 
profiles of a representative individual of the virtual population for various DLM and GET values, 668 
respectively. Figure 8 shows that over a 100-fold range of DLM values only slight or almost no 669 
differences in Cmax (69.7-74.0 mg/L) or AUC (1175-1177 mg/L·h) are observed. Tmax (1.40-2.65 h) seems 670 
to be more sensitive to in vivo dissolution changes (as reflected in the SDLM values) than the other PK 671 
parameters. Figure 9 clearly demonstrates that variation in GET markedly affects Cmax (52.2-75.5 mg/L) 672 
and tmax (1.09-4.00 h), whereas AUC (1172-1180 mg/L·h) is not impacted. 673 
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As one would anticipate, PSA on dissolution rate in the stomach revealed no changes in the simulated 674 
Cmax, tmax and AUC (data not shown), since poorly soluble weakly acidic compounds like naproxen barely 675 
dissolve in the fasted state gastric environment (see also Figure 6). 676 
 677 
Table 9: Mean in silico population pharmacokinetic (popPBPK) parameters of naproxen simulated plasma-concentration-678 
time profiles under all tested in vivo dissolution inputs (DLM scalar values) as obtained from model-based analysis of the in 679 
vitro data (see formulation and dissolution medium). 680 
 681 






Figure 7: Population mean simulated naproxen plasma concentration-time profiles and the 5th and 95th percentiles for the two 
extremes of the estimated SDLM values: (a) SDLM=1 (green and grey solid lines, respectively) and  (b) DLM=0.0022 (blue and light 
grey dashed lines, respectively). In a worst/ best case virtual bioequivalence scenario of simulated healthy adult populations 
(a) was treated as the reference, whereas (b) as the test formulation. Observed clinical data from Charles & Mogg (circles), 
Zhout et al. (squares), Haberer et al. (a) (diamonds), Setiawati et al. (triangles), Rao et al. (crosses) and Haberer et al. (b) 
(asterisks) are overlaid for verification of the PBPK model performance and comparisons. Simulations run for 72 h, but to 
enable better comparison only the first 24 hours are plotted. 
Figure 8: Sensitivity analysis of naproxen simulated plasma concentration-time profiles of population representative individual 
on DLM scalar values ranging from 0.001 (blue solid line) to 0.1 (dashed line). The values of all other parameters were kept 
constant (GET=0.25 h). Observed clinical data from Charles & Mogg (circles), Zhout et al. (squares), Haberer et al. (a) 
(diamonds), Setiawati et al. (triangles), Rao et al. (crosses) and Haberer et al. (b) (asterisks) are overlaid for comparisons. 




3.6 Virtual Bioequivalence 689 
 690 
Multiple non-replicated, two-sequence, two-treatment, two-period, cross-over virtual bioequivalence 691 
trials (n=10) with 12 individuals per trial were conducted. In a worst/ best case scenario, two 692 
hypothetical naproxen formulations with extremely different in vivo dissolution rates were tested with 693 
the aim of designing a clinically relevant safe space. The reference (R) was assumed to have a DLM 694 
scalar value of 1, corresponding to the instantaneous dissolution of naproxen sodium API powder, 695 
while the test (T) formulation was assigned the value of 0.0022, corresponding to the very slow 696 
dissolution of naproxen free acid API powder in FaSSIF V3 Level I (Table 11). 697 
Figure 10 presents the results of virtual bioequivalence trials for Cmax, AUC calculated up to the last 698 
simulated time point (AUCtlast) and extrapolated to infinity (AUCinf). Bioequivalence with regard to tmax 699 
was also investigated. In all trials, Cmax, AUCtlast, AUCinf met the average bioequivalence criteria (80-700 
125%) with confidence intervals (CI) narrowly distributed around unity, especially for AUC. However, 701 
in terms of tmax bioequivalence failed in all 10 trials and most CI were far beyond the bioequivalence 702 
limits. These findings suggest that naproxen formulations which reach 85% dissolved in media 703 
simulating the healthy human upper small intestine within 90 minutes or less are expected to be 704 
bioequivalent. These borders correspond to the dissolution “safe space” and can be used to set 705 
clinically relevant dissolution specifications to minimize the risk of bioequivalence failure. 706 
Figure 9: Sensitivity analysis of naproxen simulated plasma concentration-time profiles of population representative individual 
on GET values in fasted state ranging from 0.1 (blue solid line) to 2 hours (dash double dotted line). The values of all other 
parameters were kept constant (DLM= 1). Observed clinical data from Charles & Mogg (circles), Zhout et al. (squares), Haberer 
et al. (a) (diamonds), Setiawati et al. (triangles), Rao et al. (crosses) and Haberer et al. (b) (asterisks) are overlaid for 
comparisons. Simulations run for 72 h, but to enable better comparison only the first 24 hours are plotted. 
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Table 11: Mean in silico population pharmacokinetic (popPBPK) parameters of naproxen virtual clinical trials for the 707 




  712 
Figure 10: Average virtual bioequivalence results (% Geometric mean T/R ratio) of 10 trials with 12 simulated 
individuals in each trial. Intra-subject variability of 30% was arbitrarily chosen and added through Simcyp® (V18.1; 
Certara, Sheffield, UK) VBE module (V1.0) to the mean GET, pH of fasted stomach, pH and bile salts concentration of 
fasted duodenum, jejunum I and II. The 80-125% bioequivalence limits (red dashed lines) and the area of acceptance 
(light green shaded area) are shown for each tested PK parameter: (A) Cmax, (B) AUCtlast (AUC calculated up to the last 
simulated time point), (C) AUCinf (AUC extrapolated to infinity) and (D) tmax. Error bars represent the 90% confidence 
intervals, which in subplots (B) and (C) lie within the symbols. 
Figure 11:  Dissolution safe space for anticipated bioequivalence to naproxen products. The light green shaded area 
delimits the safe space area in which bioequivalence (with respect to Cmax and AUC) was established between the very 
slow (red solid line & squares) and the fast (blue solid line & circles) dissolution profiles. Additional typical dissolution 




4 Discussion 714 
 715 
The present study proposes a workflow and highlights the key role of mechanistic absorption and 716 
population-based PBPK modeling to establish virtual bioequivalence and set clinically relevant 717 
dissolution specifications by combining in vitro, in vivo and in silico methods.  718 
In the naproxen case example, starting from in vitro solubility and dissolution data, an approach of 719 
stepwise sequential estimation/confirmation of biopharmaceutical parameters was followed,(Pathak 720 
et al., 2019) before applying them to the PBPK model. In vitro dissolution profiles in conventional and 721 
biorelevant media were translated to different in vivo dissolution scenarios by implementing an in 722 
vitro-in vivo-extrapolation (IVIVE) strategy. The healthy adult PBPK model for naproxen was developed 723 
by optimizing post-absorptive parameters from intravenous in vivo data which was then coupled with 724 
the ADAM model for mechanistic oral absorption modelling. The verification of the PBPK model was 725 
based on its ability to predict the observed plasma PK profiles after oral administration of naproxen in 726 
several in vivo studies and its performance under multiple in vivo dissolution scenarios was assessed.  727 
Simulations of the clinical studies in conjunction with sensitivity analysis on the DLM scalar and gastric 728 
emptying time revealed that Cmax and AUC are rather insensitive to dissolution changes, but that Cmax 729 
is considerably affected by variations in gastric emptying time. However, changes in either the SDLM or 730 
gastric emptying markedly altered tmax. These results indicate that the absorption and thus the in vivo 731 
performance of naproxen formulations seem to be governed by gastric emptying, but is not 732 
dissolution-limited. This is supported by the (refined) developability classification system (DCS/ 733 
rDCS),(Butler and Dressman, 2010; Rosenberger et al., 2019) according to which naproxen would more 734 
appropriately be classified as rDCS/ DCS I, and is in excellent agreement with the study of Charles and 735 
Mogg(Charles and Mogg, 1994), which  concluded that two naproxen products (tablet and caplet) with 736 
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very dissimilar in vitro dissolution behavior were bioequivalent. Furthermore, a DLM scalar range from 737 
0.0022 to 1 translated to an increase in Cmax only by 1.06 and 1.75 times earlier tmax, assuming the 738 
default in Simcyp particle radius of 10 μm. The AUC remained unchanged. In this case, the insensitivity 739 
of PK metrics to the dissolution rate was attributed both to the absence of saturable first pass 740 
extraction and the relatively long half-life (t1/2≈20 h) of the drug. 741 
Once enough confidence with the performance of the PBPK model was achieved, several VBE trials 742 
simulating a worst/best case scenario were performed. A safe space and a clinically relevant 743 
dissolution specification for naproxen products was proposed based on the outcome of these virtual 744 
trials. It was demonstrated that 85% dissolved reached within 90 minutes lies comfortably within a 745 
region of dissolution performance where bioequivalence is anticipated and is not anywhere near the 746 
edge of failure for either Cmax or AUC. On the other hand, bioequivalence in tmax failed in all cases. In 747 
this study, in vitro dissolution of unformulated free acid and sodium salt forms of naproxen were used 748 
to simulate the worst/best case BE scenario. Although this constitutes an extreme limitation, it was 749 
done intentionally to challenge the VBE result, since if the VBE were to be based solely on the 750 
dissolution of the formulations, the safe space would be biased towards an already (partly) optimized 751 
formulation range.  752 
Virtual bioequivalence studies have been already published in the recent past(Babiskin and Zhang, 753 
2015; Doki et al., 2017; Pathak et al., 1997; Pepin et al., 2016; Wedagedera et al., 2017; Zhang et al., 754 
2017) However, in most of those studies the intra-subject (IIV) and inter-occasion (IOV) variability is 755 
either ignored or added directly to the PK metrics (i.e. Cmax and AUC) as random error terms. By 756 
contrast, in the current study the intra-subject variability was added via the Simcyp® v18.1 VBE module 757 
1.0 in several key absorption parameters, such as gastric emptying time, pH of fasted stomach, pH and 758 
bile salts concentration of fasted duodenum, jejunum I and II, and mechanistically propagated in 759 
simulations. In the context of challenging the establishment of bioequivalence, IOV was set to a 760 





5 Conclusion 764 
 765 
Mechanism-based absorption PBPK modeling can be considered as a promising and powerful 766 
bioequivalence risk assessment tool. This work highlights the importance of linking translational 767 
absorption modeling with population PBPK to examine VBE and set clinically relevant specifications. 768 
For naproxen, it was demonstrated that bioequivalence failure due to dissolution is unlikely for 769 
naproxen products because of the wide safe space. The example of naproxen illustrates that the impact 770 
of formulation on the in vivo performance is not always correlated with the in vitro dissolution 771 
behavior.  772 
To the best of our knowledge, this is the first work which not only mechanistically incorporates inter-773 
occasion variability in VBE assessment, but also propagates IOV in the simulations. Implementation of 774 
hierarchical levels of variability (BS, WS, IOV) in VBE trials is of critical importance in order to accurately 775 
describe the population variability and avoid biased, overoptimistic bioequivalence results due to 776 
underestimation of the overall variability. Even though mixed effect modelling is rare in this context, 777 
this study highlights the importance of mechanistically assigning between-subject and inter-occasion 778 
variability values which are physiologically plausible and meaningful. Using %CV values obtained from 779 
single observation in each individual within a specific population is not representative of the 780 
population BS or IOV since it comes solely from a single sample. In this case, the applied coefficient of 781 
variation is often conveniently misinterpreted as mixture of BS and IO variability. Likewise, 782 
implementation of arbitrary CV% values is inappropriate. 783 
Moving a step further towards linking the lab to the patient, mechanistic extrapolation of in vitro data 784 
(e.g. dissolution) to the in vivo situation, as explicitly demonstrated for naproxen, is critical for the 785 
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validity and interpretation of VBE results. In the context of bioequivalence trial simulation, which is of 786 
great interest for both regulatory agencies and the pharmaceutical industry, a mechanistic IVIVE 787 
approach will be essential to enable extrapolation to specific or disease populations, given that 788 
differences in factors like GI physiology need to be taken into account. The acquisition of further clinical 789 
data (e.g., intraluminal and plasma concentrations) as well as advancement of the current 790 
biopharmaceutic tools are expected to significantly increase the reliability of virtual bioequivalence 791 
results in a variety of diseases, dosing conditions such as PPI co-administration and specific populations 792 
such as pediatric patients. 793 
Consideration of drug-related pharmacokinetic characteristics (e.g., half-life, first pass effect, protein 794 
binding) along with PBPK modeling will assist not only to select the most appropriate dosage form and 795 
to set formulation targets, but more importantly to understand to what extent the formulation can be 796 
expected to steer the in vivo performance of the drug product. Further validation of the proposed 797 
approach with a range of drugs and formulations is needed to increase confidence and spread 798 
awareness of the power of mechanistic absorption modeling and PBPK in formulation design and 799 
regulation. 800 
Bridging the gap between in vitro, in vivo and in silico by applying mechanistic absorption coupled with 801 
population PBPK modeling can guide model-informed formulation selection, allow for robust clinical 802 
outcome predictions, inform regulatory decision-making, permit regulatory flexibility (e.g. granting 803 
biowaivers for some BCS class II weak acids like naproxen) and potentially reduce the cost/time of 804 
product development by replacing unnecessary clinical trials. 805 
Future work could investigate the impact of bioinequivalence in tmax on the onset of action and 806 
therefore the therapeutic equivalence of naproxen products. As has already been 807 
highlighted,(Cristofoletti et al., 2018; Loisios-Konstantinidis et al., 2019) a scenario is foreseen in which 808 
by combining verified PBPK with pharmacodynamic (PD) models tailored to the target population(s), 809 
release testing in the laboratory will be linked to the therapeutic outcome. 810 
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Figure 11:  Dissolution safe space for anticipated bioequivalence to naproxen products. The light 1127 
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Table 1: Composition and physicochemical characteristics of biorelevant media in the fasted and fed states. 1167 






















— 0.08 3.0 — 1,4 — — 15 10 
Sodium Glycocholate 
(mM) 
— — — — 1,4 — — — — 
Glyceryl monooleate 
(mM) 
— — — — — — — — 5 
Sodium Oleate (mM) — — — — 0,315 — — — 0.8 
Lecithin (mM) — 0.02 0.75 — 0,035 — — 3.75 2 
Lysolecithin (mM) — — — — 0,315 — — — — 
Cholesterol (mM) — — — — 0,2 — — — — 
Pepsin (mg/mL) — 0.1 — — — — — — — 
Sodium dihydrogen 
phosphate (mM) 
— — 28.7 13,51 13,51 — — — — 
NaOH (mM) — — 13.8 3,19 3,19 — 101 101 102.4 
Acetic acid (mM) — — — — — 18.31 144 144 — 
Maleic acid (mM) — — — — — — — — 71.9 
Sodium acetate (mM) — — — — — 32.98 — — — 
Lipofundin®: buffer — — — — — 8.75: 91.25 — — — 





— — — q.s. pH 5 — — — 
Sodium chloride (mM) — 34.2 106 — 91,62 181.7  — 204 125.5 
Osmolality (mOsm/kg) — 121 270 — 215 400 — 635 390 
Buffer capacity (HCl) 
((mmol/L)/ΔpH) 
n.a. n.a. 12 5,6 5,6 25 76 76 25 
pH 1,6 1.6 6.5 6,7 6,7 5.0 5.0 5.0 5.8 
q.s.- quantum satis; n.a.- not applicable 1168 
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  1175 










Intravenous         
(Runkel et al., 1973, 
1972a, 1972b) 
93 mg with 30μC tritium 
label in 100 mL 
phosphate buffer 
3 0.33 Caucasian HV ─ 49.9-86.3 ─ 
Oral         
(Charles and Mogg, 
1994) 
Naprosyn® 500 mg 16 0.125 Caucasian HV 22.1 (4.4) 67.6 (8.3) 175.7 (9.0) 
(Zhou et al., 1998) Naprosyn® 2 x 250 mg 10 0 Chinese HV 19-38 51-74 ─ 
Haberer et al. 
(a)(Haberer et al., 2010) 
Anaprox® 550 mg 8 0.63 Caucasian HV 44.3 (8.5) 71.44 (12.3) ─ 
(Setiawati et al., 2009) Anaprox® 550 mg 26 0.15 Caucasian HV 19-46 ─ ─ 
(Rao et al., 1993) IR Naproxen 500 mg 12 0 Indian HV 18-22 46-62.5 160-182.5 
Haberer et al. 
(b)(Haberer et al., 2010) 
IR Naproxen-Na 500 mg 16 0.63 Caucasian HV 44.3 (8.5) 71.44 (12.3) ─ 
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Table 3: Input parameters for naproxen PBPK model development and simulations 1176 
Parameters Value Reference/ Comments 
Physicochemical & Blood Binding   
MW (g/mol) 230.3 PubChem 
logPo:w 3.2 (Bergström et al., 2014; Pérez et al., 2004; 
Zhao et al., 2001) 
pKa 4.43 estimated from in vitro data (see section 3.2) 
Blood/ Plasma ratio 0.55 (Brown et al., 2007) 
Fraction unbound in plasma 0.01 (Davies and Anderson, 1997; Paixão et al., 
2012) 
Absorption   
Model ADAM  
Peff, human (x10-4 cm/s) 8.5 (Lennernas et al., 1995) 
Formulation type Immediate Release  
In vivo dissolution see Table 7,Table 8 estimated DLM scalars from in vitro data (see 
section 3.3.2) 
S0 (mg/mL) 0.0294 in vitro data (see section 3.1) 
Particle density (g/mL) 1.20 Default value within ADAM 
Particle size distribution Monodispersed Assumed as data not available 
Particle radius (μm) 10 Default value within ADAM 
logKm:w neutral 5.37 estimated from in vitro data (see section 3.2) 
logKm:w ion 4.00 estimated from in vitro data (see section 3.2) 
Distribution   
Model Minimal PBPK with SAC 
Vss (L/kg) 0.15 PE module 
57 
 
Vsac (L/kg) 0.075 PE module 
Qsac (L/h) 1.00 PE module 
Elimination   
CLiv (L/h) 0.40 PE module 
CLrenal (L/h) 0.02 (Paixão et al., 2012) 
 1177 




Table 4: Mean (± SD) equilibrium solubility in aqueous media at 37°C for 24h (Uniprep® method). 1180 
 Naproxen Naproxen Sodium 
Aqueous medium pHfinal Solubility (μg/mL) pHfinal Solubility (μg/mL) 
Water 4.5 70.4 (1.2) 6.7 358.4 (18.1) 
HCl acid (pH=1.2) 1.3 29.4 (6.4) 1.2 28.4 (0.72) 
Acetate buffer (pH=4.5) 4.5 84.8 (4.2) 4.6 103.1 (3.6) 
Level I FeSSIF V1 (pH=5.0) 5.0 175.4 (0.0202) 5.1 241.6 (5.2) 
Phosphate buffer (pH=6.5) 6.2 1627.6 (31.5) 6.6 2363.4 (31.5) 
Phosphate buffer(pH=6.8) 6.5 3619.1 (112.6) 6.9 4957 (119) 
Phosphate buffer (pH=7.4) 6.8 5981.6 (28.0) 7.5 10128 (674) 
 1181 
  1182 
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Table 5: Mean (± SD) equilibrium solubility in fasted and fed state biorelevant media at 37°C for 24h (Uniprep® method). 1183 
  Naproxen  Naproxen Sodium 






Fasted state     
     
Level III FaSSGF (pH=1.6) 1.6 33.4 (1.1) 1.6 31.8 (0.92) 
Level II FaSSIF V1 (pH=6.5) 5.9 2046 (150) 6.5 3587 (179) 
Level II FaSSIF V3 (pH=6.7) 5.8 1624 (153) 6.7 3469 (187) 
     
Fed state     
     
Level II FeSSGFmiddle (pH=5.0) 4.9 352.6 (21.4) 5.1 575.2 (19.3) 
Level II FeSSIF V1 (pH=5.0) 5.0 424.7 (26.6) 5.0 519.9 (18.9) 
Level II FeSSIF V2 (pH=5.8) 5.8 890.0 (56.7) 5.8 799.5 (177) 
 1184 
  1185 
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Table 6: Parameter estimates (95% CI) resulting from the model-based analysis of in vitro solubility data in aqueous as well as 1186 
biorelevant media. The pka was estimated from the aqueous solubility values, whereas for the micelle-water partition 1187 
coefficients (logKm:w neutral, ion) estimation, biorelevant solubilities were used. The accuracy of the predictions was evaluated 1188 
with the R squared. 1189 
 pKa logKm:w neutral logKm:w ion 
Estimate (95% CI) 4.43 (4.42-4.44) 5.37 (5.34-5.40) 4.00 (3.98-4.02) 
R2 0.9990 0.9999 
 1190 




Table 7: Estimated DLM scalar values (95% CI) obtained from model-based analysis of in vitro dissolution in various media of 1193 
naproxen free acid and sodium salt pure API powder. The goodness of fit between predicted and observed dissolution profiles 1194 
was evaluated with the R squared (R2).  1195 
Dissolution Medium API Powder 
 NPX NPX Na 
   
Level I FaSSIF V3   
DLM (95% CI) 0.0022 (0.0021-0.0023) 1* 
R2 0.997 ─ 
   
Eur. Phar. Phosphate Buffer (pH=6.8)   
DLM (95% CI) 0.0136 (0.0121-0.0151) 1* 
R2 0.992 ─ 
   
Level II FaSSIF V3   
DLM (95% CI) 0.0810 (0.0651-0.0970) 1* 
R2 0.998 ─ 
* default values of DLM scalar due to very fast dissolution (>85% dissolved in 2.5 min) 
 1196 
  1197 
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Table 8: Estimated DLM scalar and first-order disintegration rate constant (kd) values (95% CI) obtained from model-based 1198 
analysis of in vitro dissolution in various media of naproxen free acid (Naprosyn®) and sodium salt (Anaprox®) formulation. In 1199 
case of dissolution without pre-treatment in a gastric medium, a first-order disintegration model was included. The goodness 1200 
of fit between predicted and observed dissolution profiles was evaluated with the R squared (R2).  1201 
Dissolution Medium Formulation 
 Naprosyn Anaprox 
   
Level I FaSSIF V3   
DLM (95% CI) 0.0296 (0.0149-0.0443) 0.0212 (0.0131-0.0294) 
kd (95% CI) 0.305 (0.123-0.487) 0.288 (0.130-0.446) 
R2 0.999 0.998 
   
Level I FaSSIF V3 (two-stage)   
DLM (95% CI) 0.0305 (0.0191-0.0308) 0.0221 (0.0174-0.0267) 
kd (95% CI) ─ ─ 
R2 0.967 0.981 
   
Level II FaSSIF V3   
DLM (95% CI) 0.0213 (0.0170-0.0255) 0.0168 (0.00996-0.0237) 
kd (95% CI) 0.702 (0.354-1.05) 0.228 (0.0975-0.358) 
R2 0.999 0.999 
   
Level II FaSSIF V3 (two-stage)   
DLM (95% CI) 0.0187 (0.0143-0.0230) 0.0158 (0.0138-0.0179) 
kd (95% CI) ─ ─ 
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Table 9: Mean in silico population pharmacokinetic (popPBPK) parameters of naproxen simulated plasma-concentration-1204 
time profiles under all tested in vivo dissolution inputs (DLM scalar values) as obtained from model-based analysis of the in 1205 
vitro data (see formulation and dissolution medium). 1206 
Formulation Medium SDLM Disintegration 
In silico mean popPBPK 
parameters 







API       
       
Naproxen       






1.80 69.0 1305 
 Level II FaSSIF V3 0.0810 ─ 1.44 69.4 1306 
Naproxen Na       
 all media 1 ─ 1.44 69.6 1306 
       
Formulation       
       
Naprosyn       
 Level I FaSSIF V3 0.0396 0.305 1.80 67.5 1277 
  0.0305 2-stage 1.80 69.2 1306 
 Level II FaSSIF V3 0.0213 0.702 1.80 67.8 1277 
  0.0187 2-stage 1.80 69.1 1306 
Anaprox       
 Level I FaSSIF V3 0.0212 0.288 1.80 67.9 1277 
65 
 
  0.0221 2-stage 1.80 69.2 1306 
 Level II FaSSIF V3 0.0168 0.228 1.80 67.7 1277 
  0.0158 2-stage 1.80 69.1 1305 
 1207 
  1208 
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Table 10: Mean (SD) pharmacokinetic parameters of naproxen in vivo studies (a Median value). 1209 
Reference Formulation & Dose In vivo mean PK parameters (SD) 
  tmax (h) Cmax (mg/L) AUC (mg/L·h) 
(Charles and Mogg, 
1994) 
Naprosyn® 500 mg 1.50a 71.4a 1211a 
(Zhou et al., 1998) Naprosyn® 2 x 250 mg 2.6 (1.5) 87.3 (15.5) 1428 (193) 
(Haberer et al., 
2010) 
Anaprox® 550 mg 1.48 75.2 1294 
(Setiawati et al., 
2009) 
Anaprox® 550 mg 1.00 (0.5-2) 72.0 (11.2) 1013 (186) 
(Rao et al., 1993) IR Naproxen 500 mg 1.36 (0.81) 69.2 (20.9) 1435 (312) 
Haberer et al. 
(b)(Haberer et al., 
2010) 
IR Naproxen-Na 500 mg 1.53 74.9 1299 
 1210 
  1211 
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Table 11: Mean in silico population pharmacokinetic (popPBPK) parameters of naproxen virtual clinical trials for the 1212 
hypothetical reference and test formulations prior to bioequivalence assessment. 1213 
Trial N°  In silico mean popPBPK parameters 
 Reference Test 










1 1.66  62.01 1249 2.26 57.66 1248 
2 1.51  65.79 1275 2.31 62.58 1273 
3 1.96 61.30 1624 2.59 59.67 1623 
4 1.58 74.97 1659 2.41 70.61 1657 
5 1.75 60.35 1785 2.84 55.14 1783 
6 1.55 72.27 1404 2.56 67.34 1403 
7 1.45 64.14 1426 2.02 62.17 1425 
8 1.39 71.03 1473 2.47 65.14 1472 
9 1.58 61.87 1340 2.26 58.88 1339 
10 1.64 62.32 1348 2.39 60.46 1347 
 1214 
  1215 
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Figure 1: 1216 
 1217 
 1218 












NPX solubility mean values- Uniprep method
(24h in 37°C)
Avdeef et al.; Chowhan M. (24h in 25°C)
NPX Na solubility mean values- Uniprep
method (24h in 37°C)
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Level II FaSSIF V3 Level I FaSSIF V3 Ph. Eur. Phosphate Buffer pH=6.8 85% dissolved
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Figure 3: 1225 
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 1227 

















 FaSSIF V3 Level II FaSSIF V3 Level I Ph. Eur. Phosphate Buffer pH=6.8 85% dissolved
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Figure 8: 1254 
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Figure 11: 1280 
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